SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sjoeberg S.)
 

Sökning: WFRF:(Sjoeberg S.) > Effect of liragluti...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006989naa a2200661 4500
001oai:research.chalmers.se:66eb855d-c573-4cfc-bdc2-f3cd9593bf94
003SwePub
008190509s2019 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/285598
009oai:prod.swepub.kib.ki.se:231019730
009oai:lup.lub.lu.se:49767fef-6d8f-4e10-b4fe-9437a4bad582
0247 a https://research.chalmers.se/publication/5158792 URI
0247 a https://doi.org/10.1002/osp4.3242 DOI
0247 a https://research.chalmers.se/publication/5101502 URI
0247 a https://gup.ub.gu.se/publication/2855982 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2310197302 URI
0247 a https://lup.lub.lu.se/record/49767fef-6d8f-4e10-b4fe-9437a4bad5822 URI
040 a (SwePub)cthd (SwePub)gud (SwePub)kid (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Ahmadi, Shilan Seyedu University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xseysh
2451 0a Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5)
264 c 2019-03-18
264 1b Wiley,c 2019
338 a electronic2 rdacarrier
520 a Aim Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated the effect of liraglutide on sagittal abdominal diameter, waist circumference, waist-to-hip ratio and adiponectin levels in people with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDI). Materials and methods In the multicentre, double-blind, placebo-controlled MDI-liraglutide trial, 124 individuals with T2D treated with MDI were randomized to either liraglutide or placebo. Basal values of weight, waist circumference, waist-to-hip ratio, sagittal abdominal diameter and adiponectin were compared with measurements at 12 and 24 weeks after randomization. Results Baseline-adjusted mean weight loss was 3.8 +/- 2.9 kg greater in liraglutide than placebo-treated individuals (p < 0.0001). Waist circumference was reduced by 2.9 +/- 4.3 cm and 0.2 +/- 3.6 cm in the liraglutide and placebo groups, respectively, after 24 weeks (baseline-adjusted mean difference: 2.6 +/- 4.0 cm, p = 0.0005). Corresponding reductions in sagittal abdominal diameter were 1.1 +/- 1.7 cm and 0.0 +/- 1.8 cm (baseline-adjusted mean difference: 1.1 +/- 1.7 cm, p = 0.0008). Hip circumference was reduced in patients randomized to liraglutide (baseline-adjusted mean difference between treatment groups: 2.8 +/- 3.8 cm, p = 0.0001), but there was no significant difference between the groups in either waist-to-hip ratio (baseline-adjusted mean difference: 0.0 +/- 0.04 cm, p = 0.51) or adiponectin levels (baseline-adjusted mean difference: 0.8 +/- 3.3 mg L-1, p = 0.17). Lower HbA1c and mean glucose levels measured by masked continuous glucose monitoring at baseline were associated with greater effects of liraglutide on reductions in waist circumference and sagittal abdominal diameter. Conclusions In patients with T2D, adding liraglutide to MDI may reduce abdominal and hip obesity to a similar extent, suggesting an effect on both visceral and subcutaneous fat. Liraglutide had greater effects on reducing abdominal obesity in patients with less pronounced long-term hyperglycaemia but did not affect adiponectin levels.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
653 a Adiponectin
653 a liraglutide
653 a predictive variable
653 a anthropometric measurements
7001 a Filipsson, Karinu Lund University,Lunds universitet,Diabetes lab,Forskargrupper vid Lunds universitet,Lund University Research Groups4 aut0 (Swepub:lu)med-kfp
7001 a Dimenaes, H.u Södra Älvsborgs Sjukhus (SÄS),Södra Älvsborg Hospital (SÄS)4 aut
7001 a Isaksson, Sofia Sterneru Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xisaks
7001 a Imberg, Henrik,d 1991u Chalmers University of Technology4 aut0 (Swepub:cth)imbergh
7001 a Sjoeberg, S.u Karolinska Institutet4 aut
7001 a Ahrén, Bou Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Diabetes,Forskargrupper vid Lunds universitet,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)med-bah
7001 a Dahlqvist, S.u NU-sjukvården,NU Hospital Group4 aut
7001 a Gustafsson, T.u Karolinska universitetssjukhuset,Karolinska University Hospital4 aut
7001 a Tuomilehto, J.u National Institute for Health and Welfare,King Abdulaziz University,Donau-Universität Krems,Danube University Krems,Finnish National Institute for Health and Welfare4 aut
7001 a Hirsch, I. B.u University of Washington,University of Washington, Seattle4 aut
7001 a Lind, Marcus,d 1976u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xostem
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org
7730 t Obesity Science and Practiced : Wileyg 5:2, s. 130-140q 5:2<130-140x 2055-2238
8564 u https://research.chalmers.se/publication/515879/file/515879_Fulltext.pdfx primaryx freey FULLTEXT
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/osp4.324
8564 u http://dx.doi.org/10.1002/osp4.324x freey FULLTEXT
8564 8u https://research.chalmers.se/publication/515879
8564 8u https://doi.org/10.1002/osp4.324
8564 8u https://research.chalmers.se/publication/510150
8564 8u https://gup.ub.gu.se/publication/285598
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:231019730
8564 8u https://lup.lub.lu.se/record/49767fef-6d8f-4e10-b4fe-9437a4bad582

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy